Latest Quote @ Mon May 5 01:53:53 (15 min delayed)
Last Day's Data
Amgen, Inc., a biotechnology company, engages in the discovery, development, manufacture, and marketing of human therapeutics based on advances in cellular and molecular biology. The company markets human therapeutic products in the areas of nephrology, supportive cancer care, and inflammatory disease. Its products primarily include EPOGEN, Aranesp, Neulasta, NEUPOGEN, and ENBREL, which is marketed under a co-promotion agreement with Wyeth in the United States and Canada. EPOGEN and Aranesp stimulate the production of red blood cells to treat anemia. Neulasta and NEUPOGEN selectively stimulate the production of neutrophils, a type of white blood cell that helps the body fight infections. ENBREL blocks the biologic activity of tumor necrosis factor (TNF) by inhibiting TNF, a substance induced in response to inflammatory and immunological responses, such as rheumatoid arthritis and psoriasis. It sells its products to healthcare providers, including clinics, hospitals, and pharmacies primarily in the United States, Europe, Canada, and Australia. Amgen has collaboration and license agreement with Memory Pharmaceuticals Corp. to produce drugs for neurological and psychiatric disorders; and a drug-discovery agreement with Galapagos Genomics NV. The company was established by Bill Bowes, Franklin Johnson, Sam Wohlsteadter, and Raymond Baddour in 1980. Amgen is headquartered in Thousand Oaks, California.